Board of Pharmacy Virtual Meeting

Date:

Thursday, 02/10/2022

Start Time:

09:00 AM

Place:

Virtual Videoconference Meeting – Zoom Webinar

Agenda

 

BOARD OF PHARMACY

Professional and Vocational Licensing Division

Department of Commerce and Consumer Affairs

State of Hawaii

 

AGENDA

 

                                                            Date:      Thursday, February 10, 2022

 

                                                            Time:      9:00 a.m.

 

                                                            Place:     Virtual Videoconference Meeting – Zoom Webinar (use link below)

                                                                           https://dcca-hawaii-gov.zoom.us/j/92493970731

                                                                          

                                                            Zoom Phone Number:         (669) 900-6833

                                                                                                         Meeting ID: 924 9397 0731

 

In light of the COVID-19 pandemic, protecting the health and safety of the community is of utmost concern. If you wish to submit written testimony on any agenda item, please email your testimony to medical@dcca.hawaii.gov or by hard copy mail to: Attn: Hawaii Medical Board, P.O. Box 3469, Honolulu, HI 96801.  We request submission of testimony at least 24 hours prior to the meeting to ensure that it can be distributed to the Board members.

 

INTERNET ACCESS:

 

To view the meeting and provide live oral testimony, please use the link at the top of the agenda. You will be asked to enter your name. The Board requests that you enter your full name, but you may use a pseudonym or other identifier if you wish to remain anonymous. You will also be asked for an email address.  You may fill in this field with any entry in an email format, e.g., *****@***mail.com.

 

Your microphone will be automatically muted. When the Chairperson asks for public testimony, you may click the Raise Hand button found on your Zoom screen to indicate that you wish to testify about that agenda item.  The Chairperson will individually enable each testifier to unmute their microphone. When recognized by the Chairperson, please unmute your microphone before speaking and mute your microphone after you finish speaking. 

 

PHONE ACCESS:

 

If you cannot get internet access, you may get audio-only access by calling the phone number listed at the top on the agenda. 

 

Upon dialing the number, you will be prompted to enter the Meeting ID which is also listed at the top of the agenda.  After entering the Meeting ID, you will be asked to either enter your panelist number or wait to be admitted into the meeting.  You will not have a panelist number.  So, please wait until you are admitted into the meeting. 

 

When the Chairperson asks for public testimony, you may indicate you want to testify by entering “#” and then “9” on your phone’s keypad.  After entering “#” and then “9”, a voice prompt will let you know that the host of the meeting has been notified.  When recognized by the Chairperson, you may unmute yourself by pressing “#” and then “6” on your phone.  A voice prompt will let you know that you are unmuted.  Once you are finished speaking, please enter “#” and then “6” again to mute yourself.

 

 

For both internet and phone access, when testifying, you will be asked to identify yourself and the organization, if any, that you represent.  Each testifier will be limited to five minutes of testimony per agenda item.

 

Instructions to attend State of Hawaii virtual board meetings may be found online at https://cca.hawaii.gov/pvl/files/2020/08/State-of-Hawaii-Virtual-Board-Attendee-Instructions.pdf.  

 

1.            Call to Order, Public Notice, Quorum – HRS §92-3 Open Meetings and HAR §16-89-70 Oral Testimony

 

2.            Chair’s Report

a.            Announcements

b.            Approval of Minutes of January 20, 2022

 

3.            Executive Officer Report

               a.            2022 Legislative Session

1)      SB 2030 Relating To Prescription Drugs

                                             Report Title:        Opioids; Naloxone; Opioid Antagonist; Pharmacists; Prescribing; Dispensing

                                             Description:         Requires a prescriber to offer a prescription of certain drugs under certain circumstances related to opioid overdose. Requires a prescriber to offer patient education under certain circumstances related to opioid overdose. Requires a pharmacist who dispenses a prescription order for an opioid to notify the individual of the potential dangers of a high dose of an opioid and to offer to dispense to the individual an opioid antagonist; provided that the individual is prescribed specific opioids at specified doses. Exempts patients in hospice or palliative care and residents of veterans community living centers. Requires a pharmacist to notify an individual receiving an opioid antagonist of the availability of generic and brand-name opiate antagonists.

2)      SB 2199 Relating To Treatment Of Coronavirus Disease 2019

Report Title:        Physicians; Pharmacists; Advanced Practice Registered Nurses; Coronavirus Disease 2019; Prescription

Description:        Protects physicians, advanced practice registered nurses, and pharmacists from civil and criminal liability for prescribing or administering early treatment for the coronavirus disease 2019 in good faith to prevent hospitalization and death.

3)      SB 2592/HB 1667 Relating to Health

Report Title:        Clinical Laboratory Directors; Pharmacies; Pharmacists; Clinical Laboratory Improvement Amendments Waived Tests

Description:         Defines “clinical laboratory director” to include certain physicians, licensed clinical laboratory scientists, and pharmacists-in-charge of pharmacies. Amends the definition of “practice of pharmacy” to include the ordering and performing of certain Clinical Laboratory Improvement Amendments waived tests.

4)      SB 3382/HB 2340 Relating to Prescriptions

Report Title:        Electronic Prescription Filing Systems

Description:        Allows the utilization of post office boxes for prescriptions by amending the definition of “address” under chapter 329, Hawaii Revised Statutes.

               b.            Hawaii Pharmacists Associations

 

4.            Applications (The Board may move into Executive Session in accordance with HRS §92-4 and §92-5(a)(1)

               and (4) “To consider and evaluate personal information relating to individuals applying for licensure;” and

               “To consult with the Board’s attorney on questions and issues pertaining to the Board’s powers, duties,

               privileges, immunities, and liabilities;”, Board will vote in Open Meeting.)

a.            Ratification List    

b.            Applications                         

 

1)            Miscellaneous Permit

i.             Fountain Plaza Pharmacy, LLC dba FountainRx

 

                              2)            Wholsale Prescription Drug Destributor

                                             i.             Medline Technologies, L.P.

 

5.            Chapter 91, HRS – Adjudicatory Matters

a.            In the Matter of the Miscellaneous Permit of Honeybee Health, Inc. ; PHA 2021-49-L, Settlement Agreement Prior to Filing of Petition for Disciplinary Action and Board’s Final Order; Exhibit “1”

 

6.            Next Meeting:        March 17, 2022

9:00 a.m.

Virtual

                                                                          

7.            Adjournment

 

 

If you need an auxiliary aid/service or other accommodation due to a disability, contact James Skizewski at (808)586-2697 and pharmacy@dcca.hawaii.gov of the Board of Pharmacy as soon as possible, preferably within two (2) business days of the meeting.  If a response is received after that date, we will try to obtain the auxiliary aid/service or accommodation, but we cannot guarantee that the request will be fulfilled. 

 

Upon request, this notice is available in alternate formats such as large print, Braille, or electronic copy.
2/1/22